Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06484868 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 2027 to Feb 2028v4
  2. Re-verified, no change to tracked fieldsv3
  3. Eligibility criteria shortened, about 2 wordsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Trial Details
NCT Number NCT06484868
Lead Sponsor Amryt Pharma
Conditions
(from sponsor)		 Partial Lipodystrophy
Related terms Lipodystrophy, Partial, Acquired
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov